Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM Reports 2005 Year End Financial Results and Accomplishments
- Expect significant newsflow in 2006 -
View HTML
Toggle Summary ZIOPHARM to Present at BioSquare 2006 in Geneva
ZIOPHARM to Present at BioSquare 2006 in Geneva NEW YORK, NY - March 2, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Barbara Wallner, Ph.D., Senior Vice President, Technical Operations and Chief Technical Officer, will present at BioSquare 2006 on Thursday, March 9, 2006 at
View HTML
Toggle Summary ZIOPHARM Treats First Patient in ZIO-201 Phase I/II in Sarcoma
-- Clinical Development Plan on Track --
View HTML
Toggle Summary ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone Marrow Transplant Meetings
ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone Marrow Transplant Meetings NEW YORK, NY - February 21, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal kidney cells
View HTML
Toggle Summary ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow Transplant Meetings
ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow Transplant Meetings NEW YORK, NY - February 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data today at the 2006 Bone Marrow Transplant Meetings in Honolulu demonstrating that ZIO-201, the Company's proprietary
View HTML
Toggle Summary ZIOPHARM to Present at Arch Investment Conference
ZIOPHARM to Present at Arch Investment Conference NEW YORK, NY - February 15, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Arch Investment Conference on Thursday, February 23, 2006 at 11:30 a.m.
View HTML
Toggle Summary ZIOPHARM Receives Second ZIO-101 Patent Issuance
ZIOPHARM Receives Second ZIO-101 Patent Issuance NEW YORK, NY - February 9, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today a second organic arsenic case has been issued as U.S. Patent No. 6995188. The patent issue follows an announcement of a notice of allowance in mid-January.
View HTML
Toggle Summary ZIOPHARM Initiates ZIO-101 Phase I/II Myeloma Study
- Company Meets Milestone for Treatment of First Patient -
View HTML
Toggle Summary ZIOPHARM Appoints Senior Vice President for Technical Operations
ZIOPHARM Appoints Senior Vice President for Technical Operations NEW YORK, NY - January 19, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the appointment of Barbara Wallner, Ph.D., as Senior Vice President, Technical Operations and Chief Technical Officer, reporting to Dick Bagley,
View HTML
Toggle Summary ZIOPHARM Receives Notice of Allowance on Key ZIO-101 Patent
ZIOPHARM Receives Notice of Allowance on Key ZIO-101 Patent NEW YORK, NY - January 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received a notice of allowance from the U.S. Patent and Trademark Organization in a second organic arsenic case, its first organic arsenic case
View HTML